JP2005509609A5 - - Google Patents

Info

Publication number

JP2005509609A5

JP2005509609A5 JP2003532536A JP2003532536A JP2005509609A5 JP 2005509609 A5 JP2005509609 A5 JP 2005509609A5 JP 2003532536 A JP2003532536 A JP 2003532536A JP 2003532536 A JP2003532536 A JP 2003532536A JP 2005509609 A5 JP2005509609 A5 JP 2005509609A5

Authority

JP

Japan

Prior art keywords

erythropoietin

mutein

terminal

glycosylated

ethylene glycol

Prior art date

2002-09-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 18
• 102000003951 Erythropoietin Human genes 0.000 claims 15
• 108090000394 Erythropoietin Proteins 0.000 claims 15
• 229940105423 erythropoietin Drugs 0.000 claims 15
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 5
• 238000000034 method Methods 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 238000004519 manufacturing process Methods 0.000 claims 3
• 229920001223 polyethylene glycol Polymers 0.000 claims 3
• 150000001413 amino acids Chemical class 0.000 claims 2
• 125000003277 amino group Chemical group 0.000 claims 2
• 230000004071 biological effect Effects 0.000 claims 2
• 210000002798 bone marrow cell Anatomy 0.000 claims 2
• 208000020832 chronic kidney disease Diseases 0.000 claims 2
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
• 210000003743 erythrocyte Anatomy 0.000 claims 2
• 238000001727 in vivo Methods 0.000 claims 2
• 210000004898 n-terminal fragment Anatomy 0.000 claims 2
• 230000000717 retained effect Effects 0.000 claims 2
• 210000001995 reticulocyte Anatomy 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 208000012124 AIDS-related disease Diseases 0.000 claims 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
• 239000004472 Lysine Substances 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 claims 1
• 208000007502 anemia Diseases 0.000 claims 1
• 210000004900 c-terminal fragment Anatomy 0.000 claims 1
• 210000004899 c-terminal region Anatomy 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 230000014509 gene expression Effects 0.000 claims 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 238000003786 synthesis reaction Methods 0.000 claims 1